In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor

The purpose of this study is to explore whether chemotherapy and targeted-therapy regimens guided by organoid drug sensitivity test can improve the outcomes of non-resectable locally advanced and metastatic Pancreatic neuroendocrine tumors. At the same time, this study will evaluate the successful stablishment rate of organoid from biopsy tissue , and explore the concordance between drug sensitivity test results and patients' treatment response

Trial Details

NCT ID
NCT06246630
Phase
NA
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥ 18 and ≤ 75 years old.
  • Histologically or cytologically confirmed locally advanced/metastatic Pancreatic Neuroendocrine Tumor
  • Surgery was considered impossible or can not receive the radical purpose.
  • Able to provide fresh tumor tissue specimens for organoid culture, including: tumor biopsy tissues, tumor surgical specimens, etcy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →